Genentech Provides Update On Avastin For Metastatic Breast Cancer Following Reviews I

[News]

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S...

More... (http://mnt.to/f/3Ph8)